Table 1

Baseline patient characteristics for EULAR good/moderate responders and non-responders after 16 weeks of adalimumab treatment

All patients (n=48)EULAR g/m (n=38)EULAR non (n=10)p Value
Age (years)50 (13)51 (13)48 (17)0.49
Female, n (%)39 (81)30 (79)9 (90)0.43
DAS285.5 (1.1)5.6 (1.1)5.0 (0.8)0.11
Erosive disease, n (%)32 (67)24 (63)7 (70)0.84
RF, n (%)31 (65)28 (74)5 (50)0.82
ACPA, n (%)33 (69)27 (71)6 (60)0.50
ESR (mm/h)20 (11–35)20 (11–36)19 (15–21)0.72
CRP (mg/dl)8 (5–19)7 (4–20)9 (6–21)0.74
Disease duration (months)58 (31–143)60 (28–143)58 (36–201)0.55
MTX dose (mg/week)19 (6.8)19 (6.5)19 (8.3)0.85
Concomitant oral GC, n (%)13 (27)8 (22)4 (40)0.18
BMI27.0 (6.1)27.4 (6.3)24.4 (4.6)0.17
Resistin (ng/ml)24 (18–30)23 (18–29)26 (18–46)0.48
Adiponectin (mg/ml)9.6 (7.7–14.0)9.4 (7.4–12.7)9.8 (8.4–17.9)0.31
Vaspin (ng/ml)0.46 (0.26–1.03)0.42 (0.26–0.97)0.65 (0.26–1.34)0.51
Visfatin (ng/ml)2.6 (1.5–3.3)2.5 (1.8–3.3)2.6 (1.0–3.2)0.49
Leptin (ng/ml)57 (31–86)57 (35–83)59 (17–101)0.95
  • Data are represented as mean (SD), median (IQR) or n (%), as appropriate. Baseline characteristics of patients with RA treated with adalimumab (40 mg subcutaneously every 2 weeks), in combination with a stable MTX dose for at least 16 weeks, are described. Patients were compared, based on clinical response—according to the EULAR response criteria—at 16 weeks resulting in good/moderate responders (g/m) and non-responders (non), with a χ2 test, unpaired Student t test or Mann–Whitney U test, as appropriate. Presence of erosive joint disease was determined by x-ray. Presence of immunoglobulin M-RF was defined as serum levels ≥12.5 IU/ml and presence of ACPA was defined as serum levels ≥25 IU/ml.

  • ACPA, anticitrullinated peptide antibody; BMI, body mass index; CRP, C reactive protein; DAS28, disease activity score evaluated in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; GC, glucocorticoid; MTX, methotrexate; RF, IgM rheumatoid factor.